Search

Displaying results 4811 - 4820 of 5040 in total
  1. Drug

    Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB22671
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  2. Drug

    Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB31654
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  3. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970.

    International brands: Saaz-DS
  4. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577].

  5. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    Food and Drug Administration (FDA) due to the fact that it has been found to induce CYP3A enzyme activity, therefore increasing the risk for serious drug interactions.

  6. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose.

  7. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.

  8. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    [A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD … [A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease

  9. Drug

    Horse chestnut

    go.drugbank.com/drugs/DB13195
    Investigational

    Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions.

  10. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication.